Recruiting

3

351

RoW

RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan

RemeGen Co., Ltd.

Gastric Cancer, HER2 Overexpressing Gastric Carcinoma

12/24

06/25

Active, not recruiting

3

528

RoW

mFOLFOXIRI plus Bevacizumab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab, mFOLFOX6 Plus Bevacizumab

Yanhong Deng

Colorectal Cancer

01/24

06/26

Recruiting

3

500

RoW

Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab, Restaging, Concomitant Chemoradiotherapy, Surgery, Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging), Induction chemotherpay with FOLFOX

Yanhong Deng

Rectal Cancer

02/26

02/26

Not yet recruiting

3

340

NA

mFOLFOXIRI, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, mFOLFOX6

Yanhong Deng

Colorectal Cancer

07/25

07/27

Recruiting

3

711

Europe, Canada, Japan, US, RoW

Dostarlimab, CAPEOX, FOLFOX

GlaxoSmithKline

Colonic Neoplasms, Neoplasms, Colon

12/28

12/30

Not yet recruiting

2

130

RoW

MAX-40279-01, regorafenib

Maxinovel Pty., Ltd.

Metastatic Colorectal Cancer

05/22

10/23

Recruiting

2

100

RoW

Toripalimab, Tuoyi

Shanghai Junshi Bioscience Co., Ltd.

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

12/22

03/23

Recruiting

2

150

RoW

Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months, Toripalimab, Celecoxib, Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months, Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months, Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months

Sun Yat-sen University

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy

04/27

04/30

Terminated

2

6

RoW

Infigratinib, BGJ398, BBP-831

LianBio LLC

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

05/24

05/24

Active, not recruiting

2

103

RoW

Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan

Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany

BRAF V600E, Metastatic Colorectal Cancer

12/23

01/25

Recruiting

2

44

RoW

Rego+Tori+Cele, Bayer AG, Innovent Biologics

Sun Yat-sen University

Colorectal Cancer, Liver Metastases, MSS

09/25

12/25

Recruiting

2

36

RoW

Surufatinib, SULANDA, Sintilimab, IBI308, Capecitabine, Capecitabine tablets

Sun Yat-sen University

Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic

11/24

11/25

Recruiting

2

143

RoW

mFOLFOXIRI + Cadonilimab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Cadonilimab (AK104), mFOLFOX6, mFOLFOXIRI

Sun Yat-sen University

Colorectal Cancer

12/24

12/25

Recruiting

2

276

RoW

LM302+Toripalimab, LM302+JS001

LaNova Medicines Zhejiang Co., Ltd.

Gastric Cancer, Pancreatic Cancer

07/25

01/26

Recruiting

1/2

320

RoW

TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab

Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb

Advanced Cancer

02/25

05/25

Not yet recruiting

1/2

74

RoW

Liposomal irinotecan, Bevacizumab, avastin

Sun Yat-sen University

Colorectal Cancer

06/25

07/26

Recruiting

1/2

152

US, RoW

EMB-01, FIT-013a

Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc

Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor

12/25

12/25

Recruiting

1

259

RoW

JMT101, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan;

Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Advanced Solid Tumor

12/21

06/22

Recruiting

1

60

RoW

SG1906

Hangzhou Sumgen Biotech Co., Ltd.

Locally Advanced Unresectable or Metastatic Solid Tumors

02/25

08/25

Recruiting

N/A

392

RoW

Radical total mesorectal excision, Salavge Adjuvant Chemoradiotherapy

Sun Yat-sen University

Chemotherapy Effect, Rectal Cancer

12/28

12/28

Recruiting

3

375

RoW

Carrellizumab + Capecitabine, Placebo + Capecitabine

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Breast Neoplasms

09/31

12/35

Active, not recruiting

3

900

RoW

HLX11, Recombinant anti-HER2 domain II humanized monoclonal antibody injection, EU-Perjeta®

Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.

Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer

11/24

12/25

Not yet recruiting

3

400

RoW

JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Breast Cancer

04/25

03/29

Recruiting

3

844

RoW

Tamoxifen, Tamoxifen citrate, Toremifene, fareston

Chinese Anti-Cancer Association, Fudan University, Henan Cancer Hospital, The First Hospital of Jilin University, Southwest Hospital, China, First Hospital of China Medical University, Guangdong Provincial People's Hospital, Harbin Medical University, First Affiliated Hospital of Chongqing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu Provincial People's Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Union hospital of Fujian Medical University, Hebei Tumor Hospital, Hunan Cancer Hospital, Affiliated Hospital of Qinghai University, Wuhan TongJi Hospital, Hainan People's Hospital, The Third Affiliated Hospital of Kunming Medical College., The Third Affiliated Hospital of Nanchang University

Breast Cancer Female

12/25

12/25

Recruiting

2

140

RoW

Pyrotinib, Epirubicin, E, Doxorubicin Hydrochloride Liposome Injection, A, Cyclophosphamide, C, Docetaxel, T, Nab paclitaxel, Placebo

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu HengRui Medicine Co., Ltd.

Breast Cancer, Hormone-receptor Positive Breast Cancer

12/25

12/28

Recruiting

1/2

196

RoW

Sentinel Lymph Node Biopsy (SLNB), SLNB, Doxorubicin, Epirubicin, Cyclophosphamide, Fludarabine, Tumor-draining lymph node-derived lymphocyte (LNL), LNL, Interleukin-2, IL-2, Nab-paclitaxel

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Breast Neoplasms

12/30

05/35

Recruiting

1

29

RoW

GNC-035

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Breast Cancer

06/25

12/25

Recruiting

1

26

RoW

BL-M07D1

Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Breast Cancer, Locally Advanced or Metastatic Solid Tumor

06/25

12/25

Not yet recruiting

1

48

NA

CircFam53B-219aa DC vaccine, camrelizumab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Breast Neoplasms

04/26

01/27

Recruiting

1

24

RoW

Sentinel Lymph Node Biopsy (SLNB), SLNB, Doxorubicin, Epirubicin, Cyclophosphamide, Fludarabine, Tumor-draining lymph node-derived lymphocyte (LNL), LNL, Interleukin-2, IL-2, Nab-paclitaxel

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Breast Neoplasms

08/26

08/31

Completed

N/A

140

RoW

Ductal lavage, Corticosteroid therapy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Granulomatous Mastitis

04/23

04/23

Not yet recruiting

N/A

20000

RoW

Fengxi Su

Breast Cancer

12/25

12/25

Recruiting

3

143

Europe, US

Intervention/Treatment

Viridian Therapeutics, Inc.

Thyroid Eye Disease

07/25

03/26

Recruiting

3

212

US

VRDN-001 10 mg/kg, VRDN-001 3 mg/kg

Viridian Therapeutics, Inc.

Thyroid Eye Disease

05/25

01/26

Recruiting

3

126

US

VRDN-003, Placebo

Viridian Therapeutics, Inc.

Thyroid Eye Disease

04/26

12/26

Recruiting

2

100

US

Carmustine 7.7Mg Wafer, GLIADEL

University of Nebraska, Arbor Pharmaceuticals, Inc.

Brain Tumor - Metastatic

12/25

12/26

Recruiting

1/2

640

RoW

YL201 for Injection

MediLink Therapeutics (Suzhou) Co., Ltd.

Advanced Solid Tumor

10/26

10/27

Recruiting

N/A

150

US

Triamcinolone delivered via injection assistance device

ACOM Labs

Acne Vulgaris

01/24

01/24

Recruiting

N/A

1410

US

Aqtual, Inc.

Rheumatoid Arthritis

06/25

12/25

Completed

N/A

40

US

Sleep extension

Washington University School of Medicine

Insulin Resistance, Obesity

07/24

07/24

Completed

N/A

100

US

Personality-Based Cognitive Behavioral Therapy

Shannon E. Sauer-Zavala

Borderline Personality Disorder

05/24

05/24

Recruiting

N/A

180

US

Remote Virtual Cardiology Program

Duke University, Ventricle Health

Heart Failure; With Decompensation

08/26

08/26

Recruiting

N/A

87

US

Telemedicine

University of Pennsylvania

Psoriatic Arthritis

02/25

02/25

Recruiting

N/A

506

US

CHOICES, eBook

University of Florida, National Human Genome Research Institute (NHGRI)

Sickle Cell Disease, Sickle Cell Trait

06/25

06/25

3

511

Europe, US, RoW

HLX10, Serplulimab, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)

Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.

Limited-Stage Small Cell Lung Cancer

07/25

12/26

Recruiting

3

170

Europe, Canada, Japan, US, RoW

Selpercatinib, LY3527723, LOXO-292, Placebo

Loxo Oncology, Inc., Eli Lilly and Company

Carcinoma, Non-Small-Cell Lung

05/27

08/32

Recruiting

1/2

280

RoW

SAF-189s, foritinib succinate

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell

12/22

03/26

Recruiting

3

522

RoW

D-1553 Tablet, Docetaxel injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non Small Cell Lung Cancer

10/26

12/27

Terminated

2

6

RoW

Infigratinib, BGJ398, BBP-831

LianBio LLC

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

05/24

05/24

Recruiting

2

60

RoW

SI-B001, AP or TP, AP chemotherapy regimen was pemetrexed combined with cisplatin, and TP chemotherapy regimen was paclitaxel combined with cisplatin., Docetaxel

Sichuan Baili Pharmaceutical Co., Ltd.

Non Small Cell Lung Cancer

06/25

06/25